Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Carcinoma, Basal Cell 8Medulloblastoma 5Recurrence 4Thrombocythemia, Essential 2Skin Neoplasms 2Primary Myelofibrosis 2Polycythemia Vera 2Ovarian Neoplasms 2Leukemia, Myeloid, Acute 2Glioma 2Glioblastoma 2Astrocytoma 2Thrombocytosis 1Stomach Neoplasms 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Pyloric Stenosis, Hypertrophic 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pinealoma 1Pancreatic Neoplasms 1Oligodendroglioma 1Neuroectodermal Tumors, Primitive 1Neuroblastoma 1Neoplasms, Neuroepithelial 1Neoplasms, Germ Cell and Embryonal 1Neoplasms, Basal Cell 1Neoplasms 1Neoplasm Metastasis 1Myeloproliferative Disorders 1

Interventions

Imatinib Mesylate 86nilotinib 59fludarabine phosphate 46Cyclophosphamide 45Mycophenolic Acid 37Whole-Body Irradiation 35Dasatinib 32fludarabine 31Tacrolimus 29Cyclosporine 24Busulfan 23Peripheral Blood Stem Cell Transplantation 22Methotrexate 20bosutinib 18Cytarabine 18Granulocyte Colony-Stimulating Factor 16Filgrastim 16Melphalan 14thymoglobulin 13Antilymphocyte Serum 13Stem Cell Transplantation 12sargramostim 11Thiotepa 11Interferon-alpha 10Cord Blood Stem Cell Transplantation 9asciminib 8Cyclosporins 8ponatinib 7Sirolimus 7Radiotherapy 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × sonidegib × Clear all
NCT01456676 2020-12-09

Nilotinib and LDE225 in the Treatment of Chronic or Accelerated Phase Myeloid Leukemia in Patients Who Developed Resistance to Prior Therapy

Novartis

Phase 1 Completed
11 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡